Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Ophthalmology · Wet Age-Related Macular Degeneration

Monitoring Your Progress: Scans and Tests

At a Glance

For wet AMD, OCT is the main monitoring scan because it can detect retinal fluid before vision changes and helps guide injection timing. Fluorescein angiography, ICG, or OCT angiography may add information about abnormal vessels or leakage, but a dry scan does not mean monitoring can stop.

Because wet age-related macular degeneration (wet AMD) is a condition that can change from week to week, your care team relies on high-tech imaging to “see” what is happening beneath the surface of your retina. These scans are the primary tools used to decide when you need an injection and whether your current treatment schedule is working [1].

The most common test you will encounter is Optical Coherence Tomography (OCT). It has become the gold standard for following wet AMD because it is fast, safe, and incredibly precise [2].

The OCT Scan: Your “Check-up” Tool

An OCT scan is a non-invasive test that uses light waves—similar to how an ultrasound uses sound—to create a highly detailed, 3D cross-section of your retina [2].

  • What to Expect: You will rest your chin on a stable platform and look at a target light. The camera scans your eye in seconds without ever touching it [3].
  • Why Every Visit? Doctors use OCT at almost every appointment because it can detect microscopic amounts of fluid before you notice any change in your vision [4]. In fact, nearly 40% of recurrences are caught on an OCT scan before the patient reports any symptoms [4].

What Your Doctor Is Looking For

When your specialist reviews your OCT scan, they are primarily looking for three signs of “wetness” or activity. Each type of fluid tells a different story about how the disease is behaving:

1. Intraretinal Fluid (IRF)

This is fluid that has leaked directly into the layers of the retina, often forming tiny pockets or “cysts” [5]. Think of this like water soaking into a sponge. IRF is usually a sign of active disease and is often associated with a greater risk of vision loss if not treated promptly [6].

2. Subretinal Fluid (SRF)

This is fluid that pools in a space underneath the retina, lifting it up like a blister [7]. While SRF still needs monitoring, research suggests that small, stable amounts of this fluid may sometimes be tolerated as long as your vision remains sharp [8][9].

3. Pigment Epithelial Detachment (PED)

A PED occurs when the layer of cells under the retina (the RPE) is pushed upward by fluid or abnormal blood vessels, creating a small “hill” on the scan [7]. PEDs can be stubborn and take a long time to flatten, even with regular treatment [10][5].

Important: A “dry” scan is encouraging, but it does not mean you are cured or that chronic monitoring ends. Your treatment decisions are based on visual function, fluid activity, bleeding, scarring, PED features, and the medication regimen, not retinal thickness alone. You should not extend or stop treatment without your specialist.

Beyond the Standard Scan: Angiography

While OCT shows the results of leakage (the fluid), other tests help your doctor see the source of the leak (the blood vessels).

  • Fluorescein Angiography (FFA) and Indocyanine-Green (ICG): Often called the “dye tests,” these are not routinely performed at every first visit. A dilated exam and OCT often establish the diagnosis; dye tests are used selectively for uncertain or atypical cases, or when PCV is suspected [11]. A dye is injected into a vein in your arm. As the dye travels through the blood vessels in your eye, a special camera takes pictures to see exactly where and how fast the vessels are leaking [12][13]. What to expect: You may experience brief discomfort, possible nausea, temporary yellow discoloration of urine/skin, and rare allergic reactions.
  • OCT Angiography (OCTA): This is a newer, “dye-free” version of angiography. It uses advanced software to detect the movement of red blood cells, mapping out the abnormal vessels without the need for an injection [14][15]. While it is faster and easier than a dye test, it cannot always show “active” leaking as clearly as an FFA [16][17].

By combining these different views, your doctor can tailor your treatment—shortening the time between injections when fluid is present, or extending the interval when your retina is “dry” [18].

Imaging Table: What Scans Can and Cannot Show

Test Can Show Cannot Show
OCT Retinal fluid (IRF/SRF), thickness, and PEDs non-invasively Active blood flow or exact leakage source as clearly as dye
FFA Retinal blood flow, exact source of leakage (using dye) Deep choroidal vessels clearly
ICG Deep choroidal vessels, very useful for PCV (using dye) Is invasive; cannot be done dye-free
OCTA Vascular structures non-invasively without dye Active fluid leakage dynamically

Common questions in this guide

What does an OCT scan show in wet AMD?
An OCT is a quick, noninvasive scan that uses light to make detailed cross-sections of the retina. It can show fluid within or under the retina and changes such as a pigment epithelial detachment, helping the eye specialist decide whether treatment timing should change.
What do intraretinal and subretinal fluid mean on an OCT?
Intraretinal fluid is fluid within the retinal layers and often indicates active wet AMD, with a higher risk of vision loss if untreated. Subretinal fluid is under the retina; small, stable amounts may sometimes be monitored when vision remains good, but your specialist makes that decision.
What is a pigment epithelial detachment on an OCT scan?
A pigment epithelial detachment is a raised area where the layer of cells beneath the retina has been lifted by fluid or abnormal blood vessels. These detachments can be slow to flatten, so your specialist will consider whether the finding is stable and whether other signs of activity are present.
Does a dry OCT scan mean my wet AMD is cured?
No. A dry scan is encouraging, but wet AMD can become active again, so your care team may continue monitoring or treatment based on your vision, scans, bleeding, scarring, and other findings. Do not lengthen the interval between injections or stop them without your specialist's advice.
Why might I need fluorescein angiography or an ICG dye test?
These tests use injected dye to show blood flow and help locate leakage or deeper abnormal vessels when an OCT or eye examination does not provide enough information. They are used selectively and may briefly cause discomfort or nausea; rare allergic reactions can occur.
How is OCT angiography different from a dye angiogram?
OCT angiography maps moving blood cells without an injection, so it is dye-free and quick. It can show abnormal vessel patterns, but it may not display active leakage as clearly as fluorescein angiography.

Get notified when new evidence is published on wet macular degeneration.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (18)
  1. 1

    Management of neovascular age-related macular degeneration: Taiwan expert consensus.

    Yeung L, Hsieh YT, Yang CH, et al.

    Journal of the Formosan Medical Association = Taiwan yi zhi 2021; (120(12)):2061-2071 doi:10.1016/j.jfma.2021.06.012.

    PMID: 34274193
  2. 2

    Optical Coherence Tomography and the Development of Antiangiogenic Therapies in Neovascular Age-Related Macular Degeneration.

    Rosenfeld PJ

    Investigative ophthalmology & visual science 2016; (57(9)):OCT14-26 doi:10.1167/iovs.16-19969.

    PMID: 27409464
  3. 3

    Optical Coherence Tomography-Angiography of Different Choroidal Neovascularization Subtypes in Wet Age-related Macular Degeneration.

    Stavrev VN, Sivkova NP, Koleva-Georgieva DN

    Folia medica 2019; (61(2)):317-326.

    PMID: 31301657
  4. 4

    Reactivation of stable neovascular age-related macular degeneration following treat-and-extend regimen discontinuation.

    Artiaga JCM, Wong SW, Menon D, et al.

    Clinical & experimental ophthalmology 2025; (53(1)):76-83 doi:10.1111/ceo.14444.

    PMID: 39354837
  5. 5

    Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration.

    Schmidt-Erfurth U, Waldstein SM, Deak GG, et al.

    Ophthalmology 2015; (122(4)):822-32.

    PMID: 25578255
  6. 6

    Macular Morphology and Visual Acuity in the Second Year of the Comparison of Age-Related Macular Degeneration Treatments Trials.

    Sharma S, Toth CA, Daniel E, et al.

    Ophthalmology 2016; (123(4)):865-75.

    PMID: 26783095
  7. 7

    Influence of pigment epithelial detachment on visual acuity in neovascular age-related macular degeneration.

    Cheong KX, Teo KYC, Cheung CMG

    Survey of ophthalmology 2021; (66(1)):68-97 doi:10.1016/j.survophthal.2020.05.003.

    PMID: 32428539
  8. 8

    IMPACT OF FLUID COMPARTMENTS ON FUNCTIONAL OUTCOMES FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Literature Review.

    Chaudhary V, Matonti F, Zarranz-Ventura J, Stewart MW

    Retina (Philadelphia, Pa.) 2022; (42(4)):589-606 doi:10.1097/IAE.0000000000003283.

    PMID: 34393212
  9. 9

    IMPACT OF RESIDUAL SUBRETINAL FLUID VOLUMES ON TREATMENT OUTCOMES IN A SUBRETINAL FLUID-TOLERANT TREAT-AND-EXTEND REGIMEN.

    Grechenig C, Reiter GS, Riedl S, et al.

    Retina (Philadelphia, Pa.) 2021; (41(11)):2221-2228 doi:10.1097/IAE.0000000000003180.

    PMID: 33830960
  10. 10

    Application of Automated Quantification of Fluid Volumes to Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration.

    Schmidt-Erfurth U, Vogl WD, Jampol LM, Bogunović H

    Ophthalmology 2020; (127(9)):1211-1219 doi:10.1016/j.ophtha.2020.03.010.

    PMID: 32327254
  11. 11

    [Update from France Macula Federation: Diagnosis of wet AMD].

    Wolff B, De Bats F, Tick S, et al.

    Journal francais d'ophtalmologie 2018; (41(9)):857-861 doi:10.1016/j.jfo.2018.05.004.

    PMID: 30348597
  12. 12

    Practical guidance for imaging biomarkers in exudative age-related macular degeneration.

    Rispoli M, Cennamo G, Antonio LD, et al.

    Survey of ophthalmology 2023; (68(4)):615-627 doi:10.1016/j.survophthal.2023.02.004.

    PMID: 36854371
  13. 13

    OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY VERSUS TRADITIONAL MULTIMODAL IMAGING IN ASSESSING THE ACTIVITY OF EXUDATIVE AGE-RELATED MACULAR DEGENERATION: A New Diagnostic Challenge.

    Coscas GJ, Lupidi M, Coscas F, et al.

    Retina (Philadelphia, Pa.) 2015; (35(11)):2219-28 doi:10.1097/IAE.0000000000000766.

    PMID: 26398697
  14. 14

    The diagnostic accuracy of OCT angiography in naive and treated neovascular age-related macular degeneration: a review.

    Perrott-Reynolds R, Cann R, Cronbach N, et al.

    Eye (London, England) 2019; (33(2)):274-282 doi:10.1038/s41433-018-0229-6.

    PMID: 30382236
  15. 15

    A review of optical coherence tomography angiography (OCTA).

    de Carlo TE, Romano A, Waheed NK, Duker JS

    International journal of retina and vitreous 2015; (1()):5 doi:10.1186/s40942-015-0005-8.

    PMID: 27847598
  16. 16

    OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY REVEALS BLOOD FLOW IN CHOROIDAL NEOVASCULAR MEMBRANE IN REMISSION PHASE OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.

    Ichiyama Y, Sawada T, Ito Y, et al.

    Retina (Philadelphia, Pa.) 2017; (37(4)):724-730 doi:10.1097/IAE.0000000000001576.

    PMID: 28248824
  17. 17

    SD-OCT AND OCTA: Distinct or Additional Information on Neovascular Activity? The COCTAEYL Study.

    Amoroso F, Miere A, Kodjikian L, et al.

    Retina (Philadelphia, Pa.) 2026; (46(7)):1203-1211 doi:10.1097/IAE.0000000000004815.

    PMID: 41759060
  18. 18

    Recommended Guidelines for Use of Intravitreal Aflibercept With a Treat-and-Extend Regimen for the Management of Neovascular Age-Related Macular Degeneration in the Asia-Pacific Region: Report From a Consensus Panel.

    Koh A, Lanzetta P, Lee WK, et al.

    Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2017; (6(3)):296-302 doi:10.22608/APO.2016125.

    PMID: 28379655

This page is for informational purposes only and does not constitute medical advice about wet AMD. Your ophthalmologist or retina specialist should interpret your scans and decide when tests or treatment are needed.

Guide contents wet macular degeneration
Research & Literature
02 Recognizing Symptoms and Understanding Progression 04 Treating Wet AMD